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Abstract Our studies have focused on the application of imaging-capable nanoparticulate agents for the 
delivery of small RNA-based tumor therapy. One example includes magnetic nanoparticles (MN), which 
have traditionally been utilized as contrast agents for magnetic resonance imaging. The probes typically 
consist of a dextran-coated superparamagnetic iron oxide core (for magnetic resonance imaging), labeled 
with Cy5.5 dye (for near-infrared in vivo optical imaging), and conjugated to synthetic small interfering 
RNA (siRNA) molecules targeting model or therapeutic genes. We have explored the potential of these 
nanoparticles as delivery modules for small interfering RNA to tumors. Furthermore, we have investigated 
the feasibility of combining the imaging and delivery capabilities of these nanoparticles for the tracking of 
siRNA bioavailability. The versatile functionalization potential of MN has allowed us to control properties of 
the agents, such as uptake mechanism and target organ distribution. The tumoral accumulation of MN-
siRNA results in a remarkable level of target-gene down-regulation. Repeated treatment with MN-siBIRC5, 
targeting the tumor-specific anti-apoptotic gene, birc5, leads to the induction of apoptosis in the tumors and 
an overall reduction in tumor growth rate. More recently, we have synthesized a second generation of 
nanoparticles, which combine the capability for high-resolution magnetic resonance imaging with detection 
by ultrasensitive surface enhanced Raman scattering. 
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1. Introduction  
 Iron oxide nanoparticles have been of 
interest for biomedical applications due to 
their functional versatility. Concrete 
applications include cellular therapy, tissue 
repair, drug delivery, hyperthermia therapy, 
MRI, magnetofection etc (Gupta and Gupta, 
2005). The literature includes numerous 
reports describing the synthesis of iron oxide 
nanoparticles via physical and chemical 
methods. Among them, wet chemistry 
procedures have been widely used, as size, 
composition, magnetic properties and shapes 
are more controllable with this method 
(Gupta and Wells, 2004). Iron oxides are 
generally prepared by co-precipitation of 
Fe2+ and Fe3+ salts in an aqueous solution. 
The anionic salt content (chlorides, nitrates, 
sulphates etc), the Fe2+ and Fe3+ ratio, pH 
and the ionic strength in the aqueous 
solution are key elements in controlling the 
size of the particles (Sjogren et al., 1994). 
One important step in the synthesis is to 
prevent the oxidation of the synthesized 
nanoparticles and protect their magnetic 
properties, which is generally established by 
carrying out the reaction in an oxygen free 
environment (under N2) (Gupta and Curtis, 
2004). The co-precipitation process is 
generally done in the presence of a surface 
coating in order to prevent the 
agglomeration of the iron oxides into 
microparticles during the synthesis. There 
have been several surface coating materials 
used for stabilizing iron oxide nanoparticles, 
among which there are synthetic and natural 
polymers, such as polyethylene glycol 
(PEG), dextran, polyvinylpyrrolidone (PVP), 
fatty acids, polypeptides, chitosin, gelatin etc 
(Gupta and Gupta, 2005).   
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2. Biomedical Applications of Iron Oxide 
Nanoparticles  
The majority of the iron oxide 
nanoparticles are intended for biomedical 
applications. Their use as contrast agents for 
MRI is particularly attractive, due to their 
high sensitivity of detection (Bulte and 
Kraitchman, 2004). MRI is a clinically 
approved noninvasive medical imaging 
method, which allows the collection of 
three-dimensional information from inside 
the body with excellent tissue contrast. Iron 
oxide nanoparticles have been used to 
observe different biological events by in 
vivo, MRI including determining the fate of 
transplanted pancreatic islets (Evgenov et 
al., 2006; Medarova et al., 2006), tumor 
progression (Medarova et al., 2009) or 
lymph node metastasis (Harisinghani et al., 
2003), etc.   
Establishing target specific contrast 
agents for MRI presents a great opportunity 
for detecting disease at the initial stages 
when therapeutic intervention has the 
highest chances of success. This is possible 
because molecular targeting of the contrast 
would accomplish the detection of the early 
phenotypic changes that define the 
pathology. Combining diagnosis and therapy 
would be even more interesting, because it 
would allow the assessment of therapeutic 
efficacy as a function of drug delivery. It is 
possible to impart all of these functionalities 
to iron oxide nanoparticles by having 
different ligands attached to the surface of 
the nanoparticles.  
There are several methods to prepare 
iron oxide nanoparticles but the focus of this 
paper is on crosslinked dextran coated 
superparamagnetic iron oxides, whose 
precursor is a clinically approved contrast 
agent (Josephson et al., 1999). The iron 
oxide nanoparticles discussed in this review 
have a ~5 nm superparamagnetic iron oxide 
core. They are coated with dextran, which is 
a biodegradable and biocompatible polymer. 
The dextran surface is further cross-linked 
using several chemical processes to 
introduce amine groups for 
functionalization. Multiple moieties 
including targeting peptides (Kumar et al., 
2010), aptamers (Yigit et al., 2007; Yigit et 
al., 2008), NIR fluorescent dyes (Pittet et al., 
2006), therapeutic materials (Wang et al., 
2011) etc. can be conjugated to iron oxide 
nanoparticles through amine terminals and 
bifunctional linkers, Figure 1. 
3. Multifunctional Imaging and Delivery 
 
 
Fig. 1. Superparamagnetic iron oxide nanoparticles coated with dextran serve as a template for conjugation of several 
molecular moieties. In this example, magnetic nanoparticles are conjugated to a tumor targeting peptide, NIR 
fluorescent dye (cy5.5) and siRNA.  
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of Iron Oxide Nanoparticles  
 
There are several examples of using iron 
oxide nanoparticles in vitro (Zhao et al., 
2003) and in vivo (Weissleder et al., 2005). 
In one example, the probe consists of 
magnetic nanoparticles (for MRI) tagged 
with Cy5.5 dye (for NIRF imaging) and 
conjugated to a synthetic siRNA duplex 
targeting green fluorescent protein (gfp). 
The probe was tested in GFP-expressing 
tumors as a model system (Medarova et al., 
2007). The probe was further conjugated to 
myristoylated polyarginine peptide (MPAP), 
which acts as a membrane translocation 
vector for increased uptake in tumor cells. 
First, in vitro experiments using green 
fluorescent protein (GFP) or control red 
fluorescent protein (RFP)-expressing tumor 
cells confirmed that gfp was down-
regulated, whereas rfp expression 
remained constant. The in vivo studies 
showed that after systematic intravenous 
administration of the probe, accumulation 
was observed in tumors. Tumor uptake 
was confirmed by MRI and in vivo optical 
imaging (Figure 2). The expression of gfp 
in the GFP expressing tumor cells was 
reduced, whereas rfp expression was not 
affected in the RFP expressing tumors, 
indicating that the effect was specific. 
These results were confirmed by in vivo 
optical imaging and quantitative RT-PCR. 
In a more clinically-relevant scenario, 
the nanoparticles carried siRNA to the 
antiapoptotic gene birc5, which encodes 
 
Fig. 2. (a) In vivo MR imaging of mice bearing bilateral 
9L-GFP and 9L-RFP tumors before and 24 h after MN-
NIRF-siGFP administration. A significant drop in T2 
relaxivity was observed in the tumors. (b) Ex vivo high-
resolution MR images of excised tumors (78 m 
isotropic). (c) In vivo NIRF optical imaging of tumor-
bearing mice. The fluorescence signal associated with the 
tumors confirmed the delivery of the MN-NIRF-siGFP 
probe to tumor tissues. (d) Ex vivo NIRF optical imaging 
showed a significantly higher fluorescence in tumors than 
in muscle tissues. (Reprinted from Medarova et al., 2007 
with permission from Nature Publishing Group). 
 
Fig. 3. Therapeutic MN-siSurvivin delivery. (a) In vivo 
MRI of mice bearing subcutaneous LS174T human 
colorectal adenocarcinoma (arrows). The significant 
drop in T2 relaxation times observed after 
administration of the nanoparticles indicated probe 
delivery. (b) The delivery of the probe to tumors was 
confirmed by the high-intensity NIRF signal on in vivo 
optical images of mice after injection of nanoparticles 
(left, white light; middle, NIRF; right,color-coded 
overlay). (c) Quantitative RT-PCR analysis of survivin 
expression in LS174T tumors after injection of 
magnetic nanoparticles conjugated to anti-Survivin 
siRNA (d) Apoptotic rates in tumor tissues. Note 
distinct areas with a high density of apoptotic nuclei 
(green) in tumors treated with probe (left), which were 
not observed in tumors treated with the control 
magnetic nanoparticles (right). (e) H&E staining of 
frozen tumor sections revealed considerable 
eosinophilic areas of tumor necrosis (N) in tumors 
treated with probe (left). Tumors treated with magnetic 
nanoparticles were devoid of necrotic tissue (right). 
Purple hematoxiphilic regions (V) indicate viable 
tumor tissues. Scale bar, 50 µm. (Reprinted from 
Medarova et al., 2007 with permission from Nature 
Publishing Group). 
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survivin. Survivin is an important 
therapeutic target because it is a member of 
the inhibitor of apoptosis protein (IAP) 
family, which shows tumor-restricted 
expression in most human neoplasms. The 
synthesized probe was administered 
intravenously into mice twice a week for 
two weeks. MRI studies before and after 
probe administration revealed that the probe 
accumulated in tumor cells, which was also 
confirmed by in vivo optical imaging. 
The specific silencing of birc5 was 
confirmed by RT-PCR. As a result, a 
noticeable increase in tumor-associated 
levels of apoptosis and necrosis was 
observed. These results demonstrated the 
applicability of the siRNA-conjugated 
nanoparticles as multifunctional therapeutic 
and imaging agents (Figure 3).  
In a similar scenario, in order to improve 
the bioavailability of the siRNA complex to 
tumor cells, the nanoparticles were 
conjugated to the MUC-1 specific EPPT 
peptide, instead of MPAP. This modification 
increases the overall nanoparticle 
availability in tumor cells (Kumar et al., 
2010). Studies with the targeted probe 
revealed that the contrast agents were taken 
up by tumor cells in vivo resulting in an 
overall slower tumor growth due to specific 
silencing of birc5 by the siRNA-
functionalized probe. 
This technology has far-reaching 
implications. By bringing imaging and 
therapy together, it can be applied to a wide 
range of diseases, which can be treated using 
intervention at the level of gene expression.  
4. Novel Applications of Iron Oxide 
Nanoparticles  
  
Although MRI is a valuable imaging tool 
due to its high resolution, it suffers from low 
sensitivity. On the other hand, fluorescence 
is a high-sensitivity detection method, which 
suffers from low resolution and background 
auto-fluorescence. Consequently, a 
multimodal imaging method combining MRI 
and optical detection with sensitivity 
equivalent to in vivo fluorescence but 
without background interference represents a 
unique advantage. To that purpose, we have 
investigated combining surface enhanced 
Raman scattering (SERS) with MRI. In 
SERS, enhanced Raman scattering signal is 
detected from molecules absorbed on rough 
metal surfaces such as gold and silver. SERS 
is particularly valuable, since it is highly 
sensitive (two orders of magnitude brighter 
than quantum dots) and the background 
interference is minimal. The advantage of 
SERS over other optical methods is reflected 
in its capability for spectroscopic detection 
and ultra-high sensitivity suitable for 
identification of single molecules under 
certain conditions. It has been shown that in 
order to obtain an in vivo SERS signature, 
 
Fig. 4. Schematic representation of the synthesis of a SERS and MRI active contrast agent, AuMN-DTTC. The process 
involves sequential reduction of gold onto the parental MN, expansion of the gold seeds, and incorporation of DTTC and 
PEG onto the gold seeds.  
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intravenous or intramuscular administration 
of as little as 50 femtomoles of SERS active 
gold nanoparticles is enough to obtain a 
distinguishing SERS signal from deep 
tissues or from tumor xenografts (Qian et al., 
2008).  
In our studies, we have synthesized 
MRI-active superparamagnetic iron oxide 
nanoparticles, stably complexed with gold 
nanoparticles (AuMN-DTTC). The gold 
nanoparticles serve as a template for a 
Raman active dye molecule to generate a 
surface-enhanced Raman scattering (SERS) 
effect (Figure 4). The synthesized probe was 
tested for its utility as a T2 weighted MRI 
contrast agent and a SERS active contrast 
agent (Yigit et al., 2011).  
In vivo MR imaging of mice injected 
intramuscularly with the probe revealed that 
AuMN-DTTC indeed could be detected by 
MRI. SERS measurements using a portable 
Raman system showed a distinct SERS 
signal associated with the injection site 
(Yigit et al., 2011). 
This agent presents novel opportunities 
for noninvasive imaging. By combining the 
two modalities, it could allow the high-
resolution, high-sensitivity in vivo detection 
of biological processes.  
4. Conclusions 
 Developing multi-functional, multi-
modal contrast agents for clinical and pre-
clinical in vivo imaging and therapy is 
important. These agents have proven 
valuable for the delivery of molecular 
therapy to tumors. Combined with their 
multimodal image-guidance capabilities, 
iron oxide nanoparticles could open up new 
possibilities for disease detection and 
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